Saudi Arabia Amidst the hype of Saudi Arabia’s embrace of innovative therapies and technologies, the concepts of access and affordability can often be forgotten. However, the Saudi government remains the dominant healthcare payer in the country and, with medicines already consuming over 20 percent of national healthcare spending, is putting increasing emphasis…

Saudi Arabia Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom now commands nearly a third of the entire MENA pharma market. But this story goes far beyond impressive numbers. Through…

Denmark Home to a score of pioneering biopharma players, Denmark has recognized its life sciences industry as a cornerstone of the economy. After forming a public-private partnership forum in 2021, the Danish Life Sciences Council (DLSC), the government laid out an ambitious strategy for the sector. The DLSC has now taken…

Mexico Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute of Social Security and Services for State Workers (ISSSTE). Aimed at expanding the reach of public services, the scheme announced…

Germany After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve as the framework for the new German government’s healthcare agenda . While the accord presents broad healthcare reforms, the key…

China As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as the population ages, that number is expected to climb. A new report from Selesta looks at the country’s current standards…

Australia Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign.   The starter’s gun has been fired for the 2025 Australian federal election, which will be held on Saturday, 3 May, just 5 days after Canada’s forthcoming national election.…

Brazil After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the Japanese drugmaker, Rodriguez will be taking on a country full of opportunities and challenges. With more dengue cases than anywhere…

Global Writing in the April 2025 edition of DIA’s Global Forum magazine, Christopher Morrison and Richard Xie of RA Capital Management L.P., introduce the recently published cost-effectiveness analyses methodology which incorporates key value elements and drivers that are omitted or incompletely captured in traditional clinical outcome assessments.   Accelerating scientific discoveries…

USA While on the surface it may look like pharmaceuticals have been spared by Donald Trump’s “Liberation Day” trade policies, drugmakers still lack a clear picture of how they will be impacted. The US president has not, as of yet, imposed “25 percent or higher” tariffs as originally pledged, but that…

Europe With the proposed Biotech Act, the European Commission (EC) is aiming to boost the EU biotech industry’s competitivity in the face of major rivals like the US and China. Tackling the EU bloc’s regulatory complexity and its barriers to funding is not an easy task, but biotech stakeholders eye the…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to…